Research programme: Syk inhibitors - ARIAD

Drug Profile

Research programme: Syk inhibitors - ARIAD

Alternative Names: Syk inhibitors research programme - ARIAD

Latest Information Update: 17 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ARIAD Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Hypersensitivity

Most Recent Events

  • 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
  • 12 Nov 2003 Discontinued - Preclinical for Allergy in USA (unspecified route)
  • 12 Nov 2003 Discontinued - Preclinical for Asthma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top